Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Elrexfio vs Tecvayli: how two US-approved medicines for multiple myeloma compare

Creator: Reserve Meds
Published: 2026-10-18

A side-by-side guide for families in the Gulf, built from the US FDA labels, Gulf drug registers and official sources.

Reviewed by the Reserve Meds clinical operations team on 18 October 2026. Facts on this page come from the current US prescribing information for each medicine.

Elrexfio vs Tecvayli: the short answer

Elrexfio and Tecvayli are both US FDA-approved for relapsed or refractory multiple myeloma and both target BCMA, but their approved uses and dosing schedules differ. No trial has compared them head to head. Your specialist decides which, if either, fits. Reserve Meds is a digital health company. We do not diagnose or prescribe.

Condition: multiple myeloma.
Main difference: Both target BCMA and are given as injections under the skin after step-up doses with hospital monitoring, but their approved uses differ.
Head-to-head evidence: none in either US label.
Price: Quote on request.

Elrexfio and Tecvayli side by side

The table summarizes each current US label. Labels are long; your specialist and hospital pharmacy work from the full text.

Feature	Elrexfio	Tecvayli
Generic name	elranatamab-bcmm^[2]	teclistamab-cqyv^[3]
Type of medicine	bispecific antibody (T-cell engager) that targets BCMA on myeloma cells and CD3 on T cells^[2]	bispecific antibody (T-cell engager) that targets BCMA on myeloma cells and CD3 on T cells^[3]
US-approved for	Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.^[2]	Adults with relapsed or refractory multiple myeloma, in two settings: with daratumumab and hyaluronidase-fihj after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, or alone after at least four prior lines including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.^[3]
First US approval (Drugs@FDA)	14 August 2023. Accelerated approval, based on response rate and durability of response; continued approval may depend on a confirmatory trial.^{[2, 4]}	25 October 2022 (first US approval). The current label does not mark either use as an accelerated approval.^{[3, 5]}
How it is given	Injection under the skin. Step-up doses of 12 mg on day 1 and 32 mg on day 4, then 76 mg on day 8 and weekly through week 24. Patients who respond move to every two weeks, and after a further 24 weeks with a maintained response, to every four weeks.^[2]	Injection under the skin by a healthcare provider. Treatment starts with step-up doses. Used alone, it continues at 1.5 mg/kg once weekly, and the dose interval may be extended to every two weeks for patients with a complete response or better for at least 6 months.^[3]
Where and what to expect	Patients should be hospitalized for 48 hours after the first step-up dose and for a 24-hour period after the second step-up dose.^[2]	Patients should be hospitalized for 48 hours after step-up dose 1 and step-up dose 2, and stay near a healthcare facility with daily monitoring for 48 hours after the first treatment dose.^[3]
Boxed warning	Yes. Cytokine release syndrome and neurologic toxicity including ICANS. Available only through the ELREXFIO REMS restricted program.^[2]	Yes. Cytokine release syndrome and neurologic toxicity including ICANS. Available only through the TECVAYLI and TALVEY REMS restricted program.^[3]

About multiple myeloma and these two medicines

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell that is part of the immune system. In time, myeloma cells collect in the bone marrow and in the solid parts of bones.^[1]

Elrexfio and Tecvayli are both bispecific antibodies that target BCMA on myeloma cells and CD3 on T cells. In the US each is available only through a restricted safety program: the ELREXFIO REMS and the TECVAYLI and TALVEY REMS.^{[2, 3]}

The main difference

Both target BCMA and are given as injections under the skin after step-up doses with hospital monitoring, but their approved uses differ. Elrexfio is approved alone after at least four prior lines, as an accelerated approval. Tecvayli is approved alone after at least four prior lines, or with daratumumab and hyaluronidase-fihj after at least one prior line. Their dosing schedules and hospital stays after the step-up doses also differ.^{[2, 3]}

The evidence behind each approval

Elrexfio. MagnetisMM-3 (NCT04649359) was an open-label, single-arm study. Its efficacy population was 97 patients who had received at least four prior lines of therapy and no earlier BCMA-directed treatment, and the measures were response rate and duration of response. A supportive group of 64 patients had already received a BCMA-directed antibody-drug conjugate or CAR T-cell therapy.^[2]

Tecvayli. MajesTEC-3 was a randomized, open-label study in 587 patients after one to three prior lines. Tecvayli with daratumumab and hyaluronidase-fihj was compared with DPd or DVd, and the label reports a statistically significant improvement in progression-free survival and overall survival. MajesTEC-1 was a single-arm study of Tecvayli alone in 110 patients, based on overall response rate.^[3]

No head-to-head trial. Neither US label reports a study that compared Elrexfio directly with Tecvayli. The trials above enrolled different patients at different stages, so their results cannot be set side by side to decide which medicine works better.

Using one after the other

The Elrexfio label reports a supportive group of 64 patients who had already received BCMA-directed treatment, either an antibody-drug conjugate or CAR T-cell therapy. The Tecvayli MajesTEC-3 study excluded patients who had received any prior BCMA-directed therapy. Neither label reports results in patients who had already received the other medicine, and neither describes using the two together. Your specialist decides the order of treatments.^{[2, 3]}

Safety: what the labels warn about

Both labels list warnings that the treating team monitors. The boxed warning row in the table above is the most serious level of warning on a US label.

Elrexfio: common side effects listed on the label include cytokine release syndrome, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea and fever.^[2]
Tecvayli: common side effects listed on the label include fever, cytokine release syndrome, musculoskeletal pain, injection site reactions, fatigue, upper respiratory tract infection, nausea and headache (when used alone).^[3]

Availability in the Gulf

Elrexfio: Saudi Arabia: listed in the SFDA drugs list (checked 17 October 2026). Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list (checked 18 October 2026). UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan
Tecvayli: Saudi Arabia: listed in the SFDA drugs list (checked 17 October 2026). Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list (checked 18 October 2026). UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Iraq

How families in the Gulf can access Elrexfio or Tecvayli

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks it, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[8, 9]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

A US safety program applies. In the US, each medicine is available only through a restricted program (Elrexfio through the ELREXFIO REMS; Tecvayli through the TECVAYLI and TALVEY REMS).^{[2, 3]} The treating hospital must be able to give the step-up doses with hospital monitoring as the label describes.

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only and we do not choose between medicines.

Ask us about Elrexfio or Tecvayli

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Which is better, Elrexfio or Tecvayli?

There is no head-to-head trial, so no one can say from the evidence that one is better. They are approved for different patients and are given differently. Your specialist decides which fits, based on prior treatment, test results and overall health.

What is the main difference between Elrexfio and Tecvayli?

Are Elrexfio and Tecvayli available in Saudi Arabia or the UAE?

Elrexfio: Saudi Arabia: listed in the SFDA drugs list (checked 17 October 2026). Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list (checked 18 October 2026). Tecvayli: Saudi Arabia: listed in the SFDA drugs list (checked 17 October 2026). Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list (checked 18 October 2026). UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.

How can a family in the Gulf get Elrexfio or Tecvayli?

Ask the treating hospital about local supply first. If the medicine is not registered, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much do these medicines cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds choose the medicine?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or choose between medicines. Your specialist and hospital make the medical decisions.

Sources

Checked on 18 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.